Flow Diversion in Aneurysms Trial: the Design of the FIAT study

June 2011
Interventional Neuroradiology;jun2011, Vol. 17 Issue 2, p147
Academic Journal
Intracranial aneurysms, particularly large and giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional, conservative, or validated approach such as coiling, parent vessel occlusion, or surgical clipping exists. Only a randomized clinical trial can answer the question of which treatment option leads to better patient outcomes. We report the design of the FIAT study, a clinical care trial aiming to compare angiographic and clinical outcomes following treatment with a Flow-Diverter or with the best conventional treatment option. The FIAT study will include both a randomized and a registry portion. Patients will be proposed randomization to either FD stenting or best conventional treatment option (observation, coiling, stenting, or clipping) as determined by the treating physician. FIAT will recruit a total of 338 patients, to show that i) FD stenting can be performed with an 'acceptable' immediate complication rate of less than 15% morbidity and mortality (defined as mRS > 2); ii) FD stenting can increase from 75 to 90% the proportion of patients with a "good outcome", defined as complete or near-complete occlusion of the aneurysm AND a good clinical outcome (mRS ≤ 2) at one year, as compared to the best conventional option. The FIAT study provides a scientific and ethical context to care for patients eligible for flowdiversion therapy.


Related Articles

  • Corrigendum to ‘The next generation of fenestrated endografts: results of a clinical trial to support an expanded indication for aortic arch aneurysm treatment’ [Eur J Cardiothorac Surg 2013;44:e156-63]†. Azuma, Takashi; Yokoi, Yoshihiko; Yamazaki, Kenji // European Journal of Cardio-Thoracic Surgery;Feb2014, Vol. 45 Issue 2, p400 

    A correction to the article "The next generation of fenestrated endografts: results of a clinical trial to support an expanded indication for aortic arch aneurysm treatment" by Takashi Azuma, Yoshihiko Yokoi and Kenji Yamazaki is presented.

  • Medtronic makes 'valiant' effort with pivotal study.  // Medical Device Daily;6/24/2011, Vol. 15 Issue 117, p1 

    The article focuses on a device called Valiant Thoracic Stent graft system designed by Medtronics which is capable of treating thoracic aortic aneurysm (TAA). It notes that the company's U.S. VALOR II study on the device delivered excellent clinical results. The study reportedly met all of its...

  • Biosensors A9 DES safe in 'real-world' patient population.  // Medical Device Daily;5/23/2011, Vol. 15 Issue 99, p4 

    The article reports that the Biolimus A9-eluting stent system called A9 DES developed by Swiss medical technology firm Biosensors was confirmed safe to use. The post-marketing surveillance (PMS) registry was initiated by the company to focus on the results of at least 1,000 patients in its...

  • Enrollment completed in two phases of Olympia registry.  // Medical Device Daily;5/16/2007, Vol. 11 Issue 94, p2 

    The article reports on the completion of the enrollment at Boston Scientific's Taxus Olympia registry for the European and Intercontinental phases of its clinical trial. The Olympia registry is enrolling patients for the company's clinical trial on Taxus Liberte drug-eluting coronary stent. The...

  • Medtronic says RESOLUTE enrollment complete.  // Medical Device Daily;11/20/2008, Vol. 12 Issue 227, p11 

    The article announces the completion of enrollment in the 2,300-patient RESOLUTE All-Comers (R-AC) clinical study of Medtronic in just six months, two months ahead of schedule, in 2008. The trial will compare the safety and efficacy of Medtronic's Endeavor Resolute drug-eluting stent (DES) with...

  • Combo stent offers safer option for high risk patients. Pedersen, Amanda // Medical Device Daily;9/27/2010, Vol. 14 Issue 187, p1 

    This article focuses on the statement issued by ObusNeich regarding the completion of patient enrollment in a randomized clinical trial of its Combo bio-engineered sirolimus-eluting stent, at the 2010 Transcatheter Cardiovascular Therapeutics Meeting. According to the company, the evaluation...

  • First patient is enrolled in Sorin's e-OPTIMA registry.  // Medical Device Daily;9/26/2008, Vol. 12 Issue 206, p1 

    The article reports on the first patient enrollment in the e-OPTIMA registry, which was designed to assess the clinical performance of the Optima drug-eluting Carbostent from the Sorin Group. The company said that the new-generation Optima DES features a delivery system that allows for optimal...

  • Tryton reports 1st enrollment in E-Tryton 150.  // Medical Device Daily;7/7/2009, Vol. 13 Issue 128, p7 

    The article reports that Tryton Medical has enrolled patients for its stent trial. E-Tryton 150 is a stent designed to provide dedicated strategy for treating atherosclerotic lesion at the side branch of bifurcation. The study will assess major adverse cardiac events at six months following the...

  • Amicus' Phase III with Amigal Short, Sweet; no Fabrazyme. Osborne, Randy // BioWorld Today;6/23/2009, Vol. 20 Issue 119, p1 

    The article reports on the Phase III trial using Amigal against Fabry disease to be conducted by Amicus Therapeutics Inc. It is noted that many expected that the company would not be able to push through with the third phase of the 60-patient, six-month trial. Under the trial, patients will be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics